Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management

PR Newswire May 12, 2022

MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

PR Newswire May 11, 2022

MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update

PR Newswire May 9, 2022

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

PR Newswire April 14, 2022

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

PR Newswire April 5, 2022

MindMed Reports Proposed Change in Auditor for 2022 Fiscal Year

Canada NewsWire March 29, 2022

MindMed Reports Full Year 2021 Financial Results and Business Highlights

PR Newswire March 28, 2022

MindMed Announces Transition of CFO

PR Newswire March 25, 2022

MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update

PR Newswire March 21, 2022

MindMed to Participate in March Investor Conferences

PR Newswire March 9, 2022

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

PR Newswire March 2, 2022

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

PR Newswire February 23, 2022

IIROC Trade Resumption - MMED

PR Newswire February 7, 2022

IIROC Trading Halt - MMED

PR Newswire February 7, 2022

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

PR Newswire January 25, 2022

MindMed Enrolls First Participant in a Study of its Session Monitoring System

PR Newswire January 18, 2022

IIROC Trade Resumption - MMED

PR Newswire January 17, 2022

IIROC Trading Halt - MMED

PR Newswire January 17, 2022

Stephen Hurst Resigns from MindMed Board of Directors

PR Newswire January 7, 2022

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

PR Newswire January 4, 2022